Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Duloxetine for Prevention of Post-ERCP Pancreatitis
NCT06860984Phase 3Recruiting
- Sponsor
- Tanta University
- Start
- Mar 2025
- Primary completion
- Jun 2027
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of duloxetine in post-endoscopic retrograde cholangiopancreatography pancreatitis (PEP) (2 arms), sponsored by Tanta University. Primary endpoint: Development of pancreatitis after the procedure at 24 hours. Started Mar 2025; status: recruiting.
02
Drugs
duloxetine
03
Conditions
post-endoscopic retrograde cholangiopancreatography pancreatitis (PEP)
Beyond the preview
Go deeper on NCT06860984.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06860984.